These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 24739602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH.
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [Abstract] [Full Text] [Related]

  • 6. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M.
    Endocr J; 2013 Oct; 60(6):733-42. PubMed ID: 23386390
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V, Staels B, Morgan JD, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H.
    J Diabetes Complications; 2013 Oct; 27(2):177-83. PubMed ID: 23116881
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group.
    Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K, SUCCESS Study Group.
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):e20-2. PubMed ID: 22055835
    [Abstract] [Full Text] [Related]

  • 14. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group.
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [Abstract] [Full Text] [Related]

  • 15. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T.
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [Abstract] [Full Text] [Related]

  • 16. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
    Kanazu S, Horie Y, Narukawa M, Nonaka K, Taniguchi T, Arjona Ferreira JC, Takeuchi M.
    Diabetes Obes Metab; 2009 Aug; 11(8):813-8. PubMed ID: 19476471
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I.
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
    Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H.
    Int J Clin Pract; 2011 Feb; 65(2):154-64. PubMed ID: 21235696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.